Luo Xiaobin, Tu Tianqi, Zhong Yali, Xu Shangyi, Chen Xiangzhou, Chen Ligang, Yang Fubing
Department of Neurosurgery, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Graduate School of Guizhou University of Traditional Chinese Medicine, Guiyang, China.
Front Genet. 2021 Mar 9;12:617350. doi: 10.3389/fgene.2021.617350. eCollection 2021.
Glioblastoma accounts for 45.2% of central nervous system tumors. Despite the availability of multiple treatments (e.g., surgery, radiotherapy, chemotherapy, biological therapy, immunotherapy, and electric field therapy), glioblastoma has a poor prognosis, with a 5-year survival rate of approximately 5%. The pathogenesis and prognostic markers of this cancer are currently unclear. To this end, this study aimed to explore the pathogenesis of glioblastoma and identify potential prognostic markers. We used data from the GEO and TCGA databases and identified five genes (, , , , and ) that could affect the survival rate of glioblastoma patients and that were differentially expressed between glioblastoma patients and non-tumors groups. Based on a variety of bioinformatics tools for reverse prediction of target genes associated with the prognosis of GBM, a ceRNA network of messenger RNA (STX1A, PTX3, MMP9)-microRNA (miR-9-5p)-long non-coding RNA (CRNDE) was constructed. Finally, we identified five potential therapeutic drugs (bacitracin, hecogenin, clemizole, chrysin, and gibberellic acid) that may be effective treatments for glioblastoma.
胶质母细胞瘤占中枢神经系统肿瘤的45.2%。尽管有多种治疗方法（如手术、放疗、化疗、生物治疗、免疫治疗和电场治疗），但胶质母细胞瘤的预后较差，5年生存率约为5%。目前尚不清楚这种癌症的发病机制和预后标志物。为此，本研究旨在探讨胶质母细胞瘤的发病机制并确定潜在的预后标志物。我们使用了来自GEO和TCGA数据库的数据，鉴定出五个基因（此处原文缺失基因名称），这些基因可影响胶质母细胞瘤患者的生存率，且在胶质母细胞瘤患者与非肿瘤组之间存在差异表达。基于多种用于反向预测与胶质母细胞瘤预后相关靶基因的生物信息学工具，构建了信使RNA（STX1A、PTX3、MMP9）-微小RNA（miR-9-5p）-长链非编码RNA（CRNDE）的ceRNA网络。最后，我们确定了五种潜在的治疗药物（杆菌肽、海柯皂苷元、氯苯咪唑、白杨素和赤霉素），它们可能是治疗胶质母细胞瘤的有效药物。
